用普拉佐辛对运动期间大心动脉直径的α-上腺素阻塞的影响
Circulation
|March 1, 1992
概括
阿尔法-1 上腺活性限制了运动期间大和小冠状动脉的扩张. 阻止这些机制进一步增强血液流动和动脉直径,改善心脏功能.
科学领域:
- 心血管生理学心血管生理学
- 运动生理学 运动生理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 已知α-上腺体机制限制了运动诱导的扩张在小冠状动脉阻力血管.
- 运动期间α-上腺体机制对大冠状动脉的影响仍未得到研究.
研究的目的:
- 为了确定阿尔法上腺体机制在运动期间对大冠状动脉直径的影响.
- 为了调查α-1上腺体阻塞是否会影响体力运动期间冠状动脉扩张.
主要方法:
- 声微观测用于测量在跑步机炼期间在仪器化狗的圆弧冠状动脉直径.
- 通过对prazosin的冠心内输液实现了α-1上腺激素阻塞.
- 在施用普拉佐辛之前和之后评估了冠状动脉阻力和动脉直径.
主要成果:
- 运动诱导了圆冠状动脉的血管扩张,并降低了冠状动脉血管阻力.
- 使用普拉佐辛的α-1上腺激素阻塞导致冠状动脉阻力进一步下降,并显著增加圆弧冠状动脉直径.
- 没有普拉佐辛的车载输液没有改变冠状动脉血管阻力或直径,证实了普拉佐辛的特定作用.
结论:
- 运动期间的α-1上腺激素活性限制了大型心上冠状动脉和小型冠状动脉阻力血管的扩张.
- 阻断α-1上腺体受体增强了运动诱导的冠状动脉血管扩张.
更多相关视频
09:32Measurement of Pulse Propagation Velocity, Distensibility and Strain in an Abdominal Aortic Aneurysm Mouse Model
Published on: February 23, 2020
09:18Doppler Ultrasound-Based Leg Blood Flow Assessment During Single-Leg Knee-Extensor Exercise in an Uncontrolled Setting
Published on: December 15, 2023
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
